LEGEND BIOTECH CORP-ADR (LEGN) Stock Price & Overview
NASDAQ:LEGN • US52490G1022
Current stock price
The current stock price of LEGN is 23.99 USD. Today LEGN is down by -7.48%. In the past month the price increased by 36.31%. In the past year, price decreased by -30.02%.
LEGN Key Statistics
- Market Cap
- 4.401B
- P/E
- N/A
- Fwd P/E
- 120.61
- EPS (TTM)
- -1.60
- Dividend Yield
- N/A
LEGN Stock Performance
LEGN Stock Chart
LEGN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LEGN. When comparing the yearly performance of all stocks, LEGN is a bad performer in the overall market: 71.13% of all stocks are doing better.
LEGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LEGN. LEGN may be in some trouble as it scores bad on both profitability and health.
LEGN Earnings
On March 10, 2026 LEGN reported an EPS of -0.16 and a revenue of 306.30M. The company missed EPS expectations (-44.48% surprise) and missed revenue expectations (-2.14% surprise).
LEGN Forecast & Estimates
24 analysts have analysed LEGN and the average price target is 63.8 USD. This implies a price increase of 165.94% is expected in the next year compared to the current price of 23.99.
For the next year, analysts expect an EPS growth of 112.43% and a revenue growth 39.54% for LEGN
LEGN Groups
Sector & Classification
LEGN Financial Highlights
Over the last trailing twelve months LEGN reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS decreased by -68.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.12% | ||
| ROE | -29.62% | ||
| Debt/Equity | 0.09 |
LEGN Ownership
LEGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.55 | 354.636B | ||
| AMGN | AMGEN INC | 15.27 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.12 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.97 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.65 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.33 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LEGN
Company Profile
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,900 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Company Info
IPO: 2020-06-04
LEGEND BIOTECH CORP-ADR
2101 Cottontail Lane
Somerset NEW JERSEY 08873 US
CEO: Ying Huang
Employees: 2900
Phone: 17328505598
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What does LEGEND BIOTECH CORP-ADR do?
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,900 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Can you provide the latest stock price for LEGEND BIOTECH CORP-ADR?
The current stock price of LEGN is 23.99 USD. The price decreased by -7.48% in the last trading session.
Does LEGN stock pay dividends?
LEGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of LEGN stock?
LEGN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is LEGEND BIOTECH CORP-ADR (LEGN) expected to grow?
The Revenue of LEGEND BIOTECH CORP-ADR (LEGN) is expected to grow by 39.54% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does LEGEND BIOTECH CORP-ADR (LEGN) report earnings?
LEGEND BIOTECH CORP-ADR (LEGN) will report earnings on 2026-05-11, before the market open.
What is the outstanding short interest for LEGEND BIOTECH CORP-ADR?
The outstanding short interest for LEGEND BIOTECH CORP-ADR (LEGN) is 20.66% of its float.